deltatrials
Terminated PHASE3 INTERVENTIONAL NCT00036816

Vaccine Therapy in Treating Patients With Melanoma of the Eye

Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Intraocular Melanoma
Interventions MART-1 antigen NA17-A antigen gp100 antigen tyrosinase peptide
Updated 5 times since 2017 Last updated: Sep 20, 2012 Started: Feb 28, 2002 Primary completion: Feb 28, 2003
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

low accrual

Other terminated trials from European Organisation for Research and Treatment of Cancer - EORTC

See all terminations from European Organisation for Research and Treatment of Cancer - EORTC

Other Intraocular Melanoma trials with similar outcome

Browse all Intraocular Melanoma trials

This PHASE3 trial investigates Intraocular Melanoma and is currently terminated or withdrawn. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 5 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Organisation for Research and Treatment of Cancer - EORTC
Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations